New Delhi: AMID The Controversy Over Deaths Of Child Asked States/UTS to ENSURE STRICT COMPLIANCE With Schedule M – Updated Good Manufacturing Practices (Gmp) – by all drug manufacturers.Srivastava, at a meeting with top health officials from all states/uts, which was also attased by the Chief by the Chief of Indian Council for Medical Research and Drug Controller General of India (DCGII) Use of cough syrups, particular for children, as most coughs are self-limiting and do not require pharmacological treatment.Health Ministry Sources said the matter has been reviewed by union health minister jp nadda, who had directed that the matter be disasseed with states/UTS to ENSURE NECESARY ANSTION.Metropolitan Survelance Unit (MSU), Nagpur, Established under Pradhan Mantri-Ayushman Bharat Heart Infrastructure Mission (PM-Abhim), Had reported a cluster of Cases and Related Deaths for Related Deaths for A Block in Chhindwara District of Madhya Pradesh A Few Days ago.The Samples of 19 Medicines which have been consumed by the child, collected from treated private practitioners and nearby retail stores. Health Ministry said chemical analysis so far indicates that nine out of 10 Samples Meet Quality Standards. However, one of them, viz cough syrup ‘Coldrif’, Contained Diethylene Glycol – Contaminant Known to Cause Serious Serious Kidney Injury IF Used in Higher Proportions – Beyondi Limit. “Cancellation of manufacturing license of the unit that supplied the specific batch of the drug has been recommended by CDSCO Based on Inspection Findings. Criminal Proceedings Ministry said.DCGI Dr Rajeev raghuvanshi reiterated the need for drug manufacturing units to strictly comply with revised schedule m for good manufacturing practices (gmp). He noted that certain firms which have applied for the government’s infrastructure upgrade have been given giving an extection Till December.
